Brief: Partner Advances Gubra Originated Obesity Triple Agonist Peptide Into Phase 2
April 28 (Reuters) - Gubra A/S GUBRA.CO: BOEHRINGER INGELHEIM ADVANCES GUBRA ORIGINATED OBESITY TRIPLE AGONIST PEPTIDE INTO PHASE 2 DEVELOPMENT Source text: ID:nMFN7CfVNK Further company coverage: GUBRA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))